https://www.selleckchem.com/pr....oducts/Gefitinib.htm
5%; MEN up to 17.5%). For inv and fc plans, the beam on time (BOT) is shortened (MET up to 7.9%; benign tumors 49.5%). The inter operator variability analysis shows similar treatment plan quality with small differences in plan efficiency (difference in BOT 1-3.3min). LGK Lightning allows to generate improved LGK treatment plans regarding plan quality with reduced BOT compared to manual forward plans. The inter operator variability showed that multiple users with different experiences can generate similar treatment plan quality using L
إعجاب
علق
شارك
